Is CVS a good stock to buy right now?

Based on our 6-factor quantitative model, CVS HEALTH Corp (CVS) receives a "Reduce" rating with a composite score of 44.8/100. It is ranked #2,054 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 29/100, Momentum 46/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for CVS?

CVS HEALTH Corp (CVS) has a "Reduce" rating and 2-star score. The composite score of 44.8 ranks it #2,054 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is CVS in?

CVS HEALTH Corp operates in the Consumer Discretionary sector (Retail industry) with a market cap of $92.22 billion. It is classified as a large-cap stock.

Does CVS pay a dividend?

Yes, CVS pays a dividend with a current yield of 3.56%. For every $1,000 invested, you would receive approximately $35.60 in annual dividend income.

What is CVS's P/E ratio?

P/E ratio data is not currently available for CVS, which may indicate the company is not yet profitable.

How profitable is CVS?

CVS's quality factor score is 50/100. Gross margin: 45.1%. ROE: -1.5% vs sector average 6.2%. Margins are moderate to low, reflecting competitive market dynamics.

How is CVS valued compared to peers?

CVS's value factor score is 29/100 (higher = cheaper). Key multiples: , EV/EBITDA 29.7x. Trading at a premium relative to peers.

What is CVS's debt level?

CVS's debt-to-equity ratio is 249%. Sector average: 89%. Elevated leverage increases credit risk.

CVS has a beta of 0.28, meaning it is less volatile than the market. Stability score: 86/100.

Does CVS have high short interest?

CVS's short interest factor score is 27/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

CVS Stock Analysis: Reduce (Score 44.8/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
CVS	+0.62%	+7.95%	+3.94%	-0.04%	+15.02%	-	-	-
Industry Proxy XLY	+0.13%	+4.38%	-1.35%	-5.46%	-39.92%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.69%	+4.34%	+3.61%	+0.32%	-14.50%	-	-	-
Alpha vs Sector	+0.49%	+3.56%	+5.30%	+5.42%	+54.94%	-	-	-

Metric	CVS	Benchmark
P/E Ratio	-89.0x	-464%
EV/EBITDA	29.7x	+505%
Price / Book	1.4x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
CASY CASEYS GENERAL STORES INC	57	50	68	67	42.2x	16.9%	24.0%	3.8%	0.3%	123.0x	$27.2B	VS
TGT TARGET CORP	53	50	70	56	16.2x	20.7%	28.4%	3.4%	-0.7%	89.0x	$54.5B	VS
APEI AMERICAN PUBLIC EDUCATION INC	53	49	58	72	78.3x	4.6%	52.8%	2.1%	6.8%	32.0x	$1.1B	VS
LINC LINCOLN EDUCATIONAL SERVICES CORP	52	50	48	75	116.7x	5.6%	59.2%	2.3%	37.4%	147.0x	$1.3B	VS
FIVE FIVE BELOW, INC	52	50	56	73	105.5x	5.4%	32.5%	3.1%	26.5%	125.0x	$13.0B	VS
IMKTA INGLES MARKETS INC	51	50	51	62	17.4x	6.2%	23.9%	1.9%	0.4%	57.0x	$1.7B	VS
PRDO PERDOCEO EDUCATION Corp	51	50	70	57	14.2x	16.7%	100.0%	20.4%	27.1%	28.0x	$2.4B	VS
MCRI MONARCH CASINO & RESORT INC	51	50	66	47	16.7x	19.7%	24.5%	19.4%	11.5%	33.0x	$1.7B	VS
FCFS FirstCash Holdings, Inc.	49	50	29	66	34.7x	10.8%	50.2%	8.0%	26.6%	98.0x	$8.4B	VS
ESCA ESCALADE INC	48	50	65	51	15.2x	9.0%	26.1%	6.2%	8.4%	11.0x	$249M	VS
CVS CVS HEALTH Corp	45	50	29	46	-	-1.5%	45.1%	-0.2%	12.8%	249.0x	$92.2B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.5%	0.4%	0.4%	0.4%	0.4%	0.4%	0.2%	0.2%	0.2%	0.2%	0.2%
Operating Margin %	0.0%	-0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%	0.1%
EBITDA Margin %	0.0%	-0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%	0.1%
Net Margin %	-0.0%	-0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-0.0%	0.0%	0.0%
FCF Margin %	1.2%	-	1.7%	-	-	-	5.0%	4.0%	3.5%	3.3%	4.5%
ROE %	-0.0%	-0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	-0.0%	0.2%	0.1%
ROA %	-0.0%	-0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-0.0%	0.1%	0.1%
ROIC %	1.9%	-3.5%	4.5%	14.2%	8.6%	13.8%	7.6%	7.5%	2.5%	12.0%	13.5%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.5%

0.4%

0.2%

Operating Margin %

0.0%

-0.0%

0.0%

0.1%

0.0%

0.1%

EBITDA Margin %

0.0%

-0.0%

0.0%

0.1%

0.0%

0.1%

Net Margin %

-0.0%

0.0%

-0.0%

0.0%

FCF Margin %

1.2%

1.7%

5.0%

4.0%

3.5%

3.3%

4.5%

ROE %

-0.0%

-0.1%

0.1%

-0.0%

0.2%

0.1%

ROA %

-0.0%

0.0%

-0.0%

0.1%

ROIC %

1.9%

-3.5%

4.5%

14.2%

8.6%

13.8%

7.6%

7.5%

2.5%

12.0%

13.5%

Line Item	TTM	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$391.8B	$372.8B	$357.8B	$322.5B	$292.1B	$268.7B	$256.8B	$194.6B	$184.8B	$177.5B	$153.3B
	—	—	$217.1B	$196.9B	$175.8B	—	—	—	—	—	—
	$176.7B	$166.5B	$140.7B	$125.6B	$116.3B	$49.0B	$45.5B	$31.5B	$28.5B	$31.0B	$26.5B
Gross Margin	45.1%	44.7%	39.3%	38.9%	39.8%	18.3%	17.7%	16.2%	15.4%	17.5%	17.3%
	—	$4.6B	—	—	—	$4.4B	$4.4B	$2.7B	$2.5B	$2.5B	$2.1B
Total Operating Expenses	—	—	$126.9B	$117.8B	$103.1B	—	—	—	—	—	—
	$3.4B	$8.5B	$13.7B	$7.7B	$13.2B	$13.9B	$12.0B	$4.0B	$9.5B	$10.4B	$9.5B
EBIT	$3.4B	$8.5B	$13.7B	$7.7B	$13.2B	$13.9B	$12.0B	$4.0B	$9.5B	$10.4B	$9.5B
EBITDA	$3.4B	$13.2B	$13.7B	$7.7B	$13.2B	$18.6B	$16.5B	$6.7B	$11.8B	$12.8B	$11.5B
Operating Margin	0.9%	2.3%	3.8%	2.4%	4.5%	5.2%	4.7%	2.1%	5.2%	5.9%	6.2%
EBITDA Margin	0.9%	3.5%	3.8%	2.4%	4.5%	6.9%	6.4%	3.5%	6.4%	7.2%	7.5%
	—	$2.5B	$2.7B	$2.3B	$2.5B	$4.3B	$3.1B	$2.6B	$1.1B	$1.7B	$838M
	—	—	$11.2B	$5.6B	$10.4B	—	—	—	—	—	—
Income Tax Expense	—	$1.6B	$2.8B	$1.5B	$2.5B	$2.6B	$2.4B	$2.0B	$1.6B	$3.3B	$3.4B
	-$1.1B	$4.6B	$8.4B	$4.2B	$7.9B	$7.2B	$6.6B	-$596M	$6.6B	$5.3B	$5.2B
Net Margin	-0.2%	1.2%	2.3%	1.3%	2.7%	2.7%	2.6%	-0.3%	3.6%	3.0%	3.4%
	$-3.13	$3.67	$6.49	$3.16	$6.00	$5.48	$5.10	$-0.57	$6.47	$4.93	$4.66
Diluted EPS	$-3.13	$3.67	$6.47	$3.14	$5.95	$5.48	$5.10	$-0.57	$6.47	$4.93	$4.66
Weighted Avg Basic	—	—	1.3B	1.3B	1.3B	—	—	—	—	—	—
Weighted Avg Diluted	—	—	1.3B	1.3B	1.3B	—	—	—	—	—	—

Line Item

TTM

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$391.8B

$372.8B

$357.8B

$322.5B

$292.1B

$268.7B

$256.8B

$194.6B

$184.8B

$177.5B

$153.3B

—

$217.1B

$196.9B

$175.8B

—

$176.7B

$166.5B

$140.7B

$125.6B

$116.3B

$49.0B

$45.5B

$31.5B

$28.5B

$31.0B

$26.5B

Gross Margin

45.1%

44.7%

39.3%

38.9%

39.8%

18.3%

17.7%

16.2%

15.4%

17.5%

17.3%

—

$4.6B

—

$4.4B

$2.7B

$2.5B

$2.1B

Total Operating Expenses

—

$126.9B

$117.8B

$103.1B

—

$3.4B

$8.5B

$13.7B

$7.7B

$13.2B

$13.9B

$12.0B

$4.0B

$9.5B

$10.4B

$9.5B

EBIT

$3.4B

$8.5B

$13.7B

$7.7B

$13.2B

$13.9B

$12.0B

$4.0B

$9.5B

$10.4B

$9.5B

EBITDA

$3.4B

$13.2B

$13.7B

$7.7B

$13.2B

$18.6B

$16.5B

$6.7B

$11.8B

$12.8B

$11.5B

Operating Margin

0.9%

2.3%

3.8%

2.4%

4.5%

5.2%

4.7%

2.1%

5.2%

5.9%

6.2%

EBITDA Margin

0.9%

3.5%

3.8%

2.4%

4.5%

6.9%

6.4%

3.5%

6.4%

7.2%

7.5%

—

$2.5B

$2.7B

$2.3B

$2.5B

$4.3B

$3.1B

$2.6B

$1.1B

$1.7B

$838M

—

$11.2B

$5.6B

$10.4B

—

Income Tax Expense

—

$1.6B

$2.8B

$1.5B

$2.5B

$2.6B

$2.4B

$2.0B

$1.6B

$3.3B

$3.4B

-$1.1B

$4.6B

$8.4B

$4.2B

$7.9B

$7.2B

$6.6B

-$596M

$6.6B

$5.3B

$5.2B

Net Margin

-0.2%

1.2%

2.3%

1.3%

2.7%

2.6%

-0.3%

3.6%

3.0%

3.4%

$-3.13

$3.67

$6.49

$3.16

$6.00

$5.48

$5.10

$-0.57

$6.47

$4.93

$4.66

Diluted EPS

$-3.13

$3.67

$6.47

$3.14

$5.95

$5.48

$5.10

$-0.57

$6.47

$4.93

$4.66

Weighted Avg Basic

—

1.3B

—

Weighted Avg Diluted

—

1.3B

—

CVS HEALTH Corp (CVS) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does CVS HEALTH Corp Do?

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island. CVS HEALTH Corp (CVS) is classified as a large-cap stock in the Consumer Discretionary sector, specifically within the Retail industry. The company is led by CEO Karen S. Lynch and employs approximately 300,000 people, headquartered in Woonsocket, Rhode Island. With a market capitalization of $92.2B, CVS is one of the prominent companies in the Consumer Discretionary sector.

CVS HEALTH Corp (CVS) Stock Rating — Reduce (April 2026)

As of April 2026, CVS HEALTH Corp receives a Reduce rating with a composite score of 44.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CVS ranks #2,054 out of 4,446 stocks in our coverage universe. Within the Consumer Discretionary sector, CVS HEALTH Corp ranks #196 of 442 stocks, placing it in the upper half of its Consumer Discretionary peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CVS Stock Price and 52-Week Range

CVS HEALTH Corp (CVS) currently trades at $79.20. The stock gained $0.36 (0.5%) in the most recent trading session. The 52-week high for CVS is $85.15, which means the stock is currently trading -7.0% from its annual peak. The 52-week low is $58.35, putting the stock 35.7% above its annual trough. Recent trading volume was 6.9M shares, reflecting moderate market activity.

Is CVS Overvalued or Undervalued? — Valuation Analysis

CVS HEALTH Corp (CVS) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.37x, versus the sector average of 1.99x. The price-to-sales ratio is 0.26x, compared to 0.27x for the average Consumer Discretionary stock. On an enterprise value basis, CVS trades at 29.66x EV/EBITDA, versus 4.91x for the sector.

At current multiples, CVS HEALTH Corp trades at a premium to most Consumer Discretionary peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CVS HEALTH Corp Profitability — ROE, Margins, and Quality Score

CVS HEALTH Corp (CVS) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -1.5%, compared to the Consumer Discretionary sector average of 6.2%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -0.4% versus the sector average of 2.5%.

On a margin basis, CVS HEALTH Corp reports gross margins of 45.1%, compared to 36.9% for the sector. The operating margin is 0.9% (sector: 3.8%). Net profit margin stands at -0.2%, versus 2.1% for the average Consumer Discretionary stock. Revenue growth is running at 12.8% on a trailing basis, compared to 3.3% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

CVS Debt, Balance Sheet, and Financial Health

CVS HEALTH Corp has a debt-to-equity ratio of 249.0%, compared to the Consumer Discretionary sector average of 89.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.83x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $79.84B. Cash and equivalents stand at $9.10B.

CVS has a beta of 0.28, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for CVS HEALTH Corp is 86/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

CVS HEALTH Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, CVS HEALTH Corp reported revenue of $391.80B and earnings per share (EPS) of $-3.13. Net income for the quarter was $-1.12B. Gross margin was 45.1%. Operating income came in at $3.38B.

In Q3 2025, CVS HEALTH Corp reported revenue of $102.87B and earnings per share (EPS) of $-3.13. Net income for the quarter was $-3.99B. Gross margin was 44.5%. Revenue grew 7.8% year-over-year compared to Q3 2024. Operating income came in at $-3.21B.

In Q2 2025, CVS HEALTH Corp reported revenue of $98.92B and earnings per share (EPS) of $0.81. Net income for the quarter was $1.01B. Gross margin was 45.4%. Revenue grew 8.4% year-over-year compared to Q2 2024. Operating income came in at $2.38B.

In Q1 2025, CVS HEALTH Corp reported revenue of $94.59B and earnings per share (EPS) of $1.41. Net income for the quarter was $1.78B. Gross margin was 46.0%. Revenue grew 7.0% year-over-year compared to Q1 2024. Operating income came in at $3.37B.

Over the past 8 quarters, CVS HEALTH Corp has demonstrated a growth trajectory, with revenue expanding from $88.44B to $391.80B. Investors analyzing CVS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CVS Dividend Yield and Income Analysis

CVS HEALTH Corp (CVS) currently pays a dividend yield of 3.6%. At this yield, a $10,000 investment in CVS stock would generate approximately $$356.00 in annual dividend income.

CVS Momentum and Technical Analysis Profile

CVS HEALTH Corp (CVS) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 27/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CVS vs Competitors — Consumer Discretionary Sector Ranking and Peer Comparison

Within the Consumer Discretionary sector, CVS HEALTH Corp (CVS) ranks #196 out of 442 stocks based on the Blank Capital composite score. This places CVS in the upper half of all Consumer Discretionary stocks in our coverage universe. Key competitors and sector peers include MONARCH CASINO & RESORT INC (MCRI) with a score of 50.5/100, CASEYS GENERAL STORES INC (CASY) with a score of 57.3/100, INGLES MARKETS INC (IMKTA) with a score of 51.0/100, FIVE BELOW, INC (FIVE) with a score of 51.6/100, and TARGET CORP (TGT) with a score of 52.6/100.

Comparing CVS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CVS vs S&P 500 (SPY) comparison to assess how CVS HEALTH Corp stacks up against the broader market across all factor dimensions.

CVS Next Earnings Date

No upcoming earnings date has been announced for CVS HEALTH Corp (CVS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CVS? — Investment Thesis Summary

The quantitative profile for CVS HEALTH Corp suggests caution. The value score of 29/100 indicates premium valuation. Low volatility (stability score 86/100) reduces downside risk.

In summary, CVS HEALTH Corp (CVS) earns a Reduce rating with a composite score of 44.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CVS stock.

Related Resources for CVS Investors

Explore more research and tools: CVS vs S&P 500 comparison, top Consumer Discretionary stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CVS head-to-head with peers: CVS vs MCRI, CVS vs CASY, CVS vs IMKTA.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap

Patients scramble to find estrogen patches as shortage worsens after US FDA champions use

Assessing CVS Health (CVS) Valuation As Shares Trade Near US$79 With Mixed Earnings Signals

Is CVS Health (CVS) Pricing Reflect Its Integrated Healthcare Potential After Recent Share Rebound

A Look At CVS Health’s Valuation As Medicare Advantage Rates Rise And FTC Insulin Concerns Ease

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Consumer Discretionary Stocks

CVS HEALTH Corp (CVS) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does CVS HEALTH Corp Do?

CVS HEALTH Corp (CVS) Stock Rating — Reduce (April 2026)

CVS Stock Price and 52-Week Range

Is CVS Overvalued or Undervalued? — Valuation Analysis

CVS HEALTH Corp Profitability — ROE, Margins, and Quality Score

CVS Debt, Balance Sheet, and Financial Health

CVS HEALTH Corp Revenue and Earnings History — Quarterly Trend

CVS Dividend Yield and Income Analysis

CVS Momentum and Technical Analysis Profile

CVS vs Competitors — Consumer Discretionary Sector Ranking and Peer Comparison

CVS Next Earnings Date

Should You Buy CVS? — Investment Thesis Summary

Related Resources for CVS Investors

Comments

Institutional Benchmarks

Get alerted on rating changes

Intelligence Feed

2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap

Patients scramble to find estrogen patches as shortage worsens after US FDA champions use

Assessing CVS Health (CVS) Valuation As Shares Trade Near US$79 With Mixed Earnings Signals

Is CVS Health (CVS) Pricing Reflect Its Integrated Healthcare Potential After Recent Share Rebound

A Look At CVS Health’s Valuation As Medicare Advantage Rates Rise And FTC Insulin Concerns Ease